Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06971913
PHASE2

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

Sponsor: Peking University People's Hospital

View on ClinicalTrials.gov

Summary

This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2025-05-20

Completion Date

2025-12-30

Last Updated

2025-05-14

Healthy Volunteers

No

Interventions

DRUG

Interleukin-2 (IL-2)

Low-dose IL-2 at 1MIU will be administered subcutaneously every other day from baseline to CMV negativity.

DRUG

Ganciclovir (GCV)

Ganciclovir injection will be administrated intravenously at a dose of 5mg/kg per day.

Locations (1)

Peking University People's Hospital

Beijing, Bejing, China